Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 21 studies | 36% ± 18% | |
astrocyte | 16 studies | 33% ± 15% | |
oligodendrocyte | 15 studies | 45% ± 16% | |
macrophage | 14 studies | 47% ± 25% | |
B cell | 13 studies | 39% ± 21% | |
microglial cell | 13 studies | 55% ± 15% | |
glutamatergic neuron | 12 studies | 42% ± 23% | |
oligodendrocyte precursor cell | 12 studies | 37% ± 17% | |
GABAergic neuron | 11 studies | 41% ± 20% | |
pericyte | 10 studies | 36% ± 15% | |
ciliated cell | 8 studies | 28% ± 11% | |
memory B cell | 8 studies | 18% ± 2% | |
retinal ganglion cell | 7 studies | 43% ± 16% | |
naive B cell | 7 studies | 23% ± 4% | |
fibroblast | 7 studies | 28% ± 15% | |
T cell | 7 studies | 37% ± 10% | |
neuron | 6 studies | 45% ± 19% | |
interneuron | 6 studies | 55% ± 18% | |
myeloid cell | 6 studies | 52% ± 15% | |
endothelial cell of lymphatic vessel | 6 studies | 49% ± 15% | |
epithelial cell | 5 studies | 36% ± 16% | |
cardiac muscle cell | 5 studies | 56% ± 13% | |
dendritic cell | 5 studies | 27% ± 6% | |
mast cell | 5 studies | 28% ± 14% | |
monocyte | 5 studies | 34% ± 10% | |
smooth muscle cell | 5 studies | 25% ± 7% | |
type II pneumocyte | 5 studies | 19% ± 4% | |
granule cell | 4 studies | 32% ± 7% | |
CD4-positive, alpha-beta T cell | 4 studies | 39% ± 11% | |
lymphocyte | 4 studies | 44% ± 21% | |
OFF-bipolar cell | 4 studies | 32% ± 14% | |
basal cell | 4 studies | 36% ± 23% | |
natural killer cell | 4 studies | 23% ± 5% | |
type I pneumocyte | 4 studies | 20% ± 4% | |
adipocyte | 4 studies | 18% ± 3% | |
ionocyte | 3 studies | 44% ± 7% | |
GABAergic interneuron | 3 studies | 42% ± 11% | |
amacrine cell | 3 studies | 23% ± 6% | |
CD8-positive, alpha-beta T cell | 3 studies | 23% ± 5% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 30% ± 11% | |
GABAergic amacrine cell | 3 studies | 32% ± 9% | |
ON-bipolar cell | 3 studies | 34% ± 15% | |
glycinergic amacrine cell | 3 studies | 27% ± 6% | |
rod bipolar cell | 3 studies | 26% ± 11% | |
endothelial cell of vascular tree | 3 studies | 27% ± 14% | |
ependymal cell | 3 studies | 47% ± 9% | |
alveolar macrophage | 3 studies | 60% ± 8% | |
capillary endothelial cell | 3 studies | 33% ± 6% | |
club cell | 3 studies | 25% ± 5% | |
respiratory goblet cell | 3 studies | 41% ± 11% | |
leukocyte | 3 studies | 61% ± 7% | |
podocyte | 3 studies | 75% ± 14% | |
mural cell | 3 studies | 45% ± 7% | |
abnormal cell | 3 studies | 29% ± 13% | |
mucus secreting cell | 3 studies | 47% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 100% | 3523.72 | 359 / 359 | 100% | 58.68 | 285 / 286 |
esophagus | 100% | 2783.33 | 1445 / 1445 | 99% | 41.86 | 182 / 183 |
intestine | 100% | 3978.74 | 966 / 966 | 99% | 68.28 | 524 / 527 |
skin | 100% | 2770.00 | 1805 / 1809 | 100% | 90.92 | 470 / 472 |
brain | 100% | 4785.97 | 2641 / 2642 | 99% | 38.90 | 700 / 705 |
breast | 100% | 2338.21 | 459 / 459 | 99% | 34.68 | 1105 / 1118 |
thymus | 100% | 2982.95 | 653 / 653 | 99% | 30.25 | 597 / 605 |
lung | 100% | 3350.23 | 578 / 578 | 98% | 36.06 | 1135 / 1155 |
bladder | 100% | 3382.95 | 21 / 21 | 98% | 35.87 | 492 / 504 |
pancreas | 99% | 2149.91 | 325 / 328 | 98% | 34.64 | 175 / 178 |
prostate | 100% | 2507.13 | 244 / 245 | 97% | 24.01 | 489 / 502 |
uterus | 100% | 2672.90 | 170 / 170 | 96% | 27.61 | 439 / 459 |
kidney | 100% | 4542.27 | 89 / 89 | 95% | 26.34 | 852 / 901 |
adrenal gland | 100% | 2806.51 | 258 / 258 | 93% | 34.37 | 214 / 230 |
ovary | 100% | 2939.57 | 180 / 180 | 92% | 22.88 | 397 / 430 |
adipose | 100% | 2564.57 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 82.35 | 80 / 80 |
spleen | 100% | 5626.89 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 8.84 | 1 / 1 |
heart | 100% | 6329.15 | 860 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3334.63 | 1332 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 28.89 | 44 / 45 |
lymph node | 0% | 0 | 0 / 0 | 97% | 35.58 | 28 / 29 |
liver | 52% | 648.94 | 117 / 226 | 43% | 9.07 | 175 / 406 |
peripheral blood | 88% | 2818.06 | 821 / 929 | 0% | 0 | 0 / 0 |
muscle | 12% | 93.82 | 95 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1904894 | Biological process | positive regulation of receptor signaling pathway via STAT |
GO_0018279 | Biological process | protein N-linked glycosylation via asparagine |
GO_1903614 | Biological process | negative regulation of protein tyrosine phosphatase activity |
GO_0006487 | Biological process | protein N-linked glycosylation |
GO_0030335 | Biological process | positive regulation of cell migration |
GO_0019082 | Biological process | viral protein processing |
GO_0000139 | Cellular component | Golgi membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0016020 | Cellular component | membrane |
GO_0004864 | Molecular function | protein phosphatase inhibitor activity |
GO_0030145 | Molecular function | manganese ion binding |
GO_0030144 | Molecular function | alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase activity |
Gene name | MGAT5 |
Protein name | alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferase (EC 2.4.1.155) Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A (EC 2.4.1.155) (Alpha-mannoside beta-1,6-N-acetylglucosaminyltransferase V) (GlcNAc-T V) (GNT-V) (Mannoside acetylglucosaminyltransferase 5) (N-acetylglucosaminyl-transferase V) [Cleaved into: Secreted alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A (Secreted beta-1,6-N-acetylglucosaminyltransferase V) (Secreted GNT-V)] |
Synonyms | GGNT5 |
Description | FUNCTION: Catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides . Catalyzes an important step in the biosynthesis of branched, complex-type N-glycans, such as those found on EGFR, TGFR (TGF-beta receptor) and CDH2 . Via its role in the biosynthesis of complex N-glycans, plays an important role in the activation of cellular signaling pathways, reorganization of the actin cytoskeleton, cell-cell adhesion and cell migration. MGAT5-dependent EGFR N-glycosylation enhances the interaction between EGFR and LGALS3 and thereby prevents rapid EGFR endocytosis and prolongs EGFR signaling. Required for efficient interaction between TGFB1 and its receptor. Enhances activation of intracellular signaling pathways by several types of growth factors, including FGF2, PDGF, IGF, TGFB1 and EGF. MGAT5-dependent CDH2 N-glycosylation inhibits CDH2-mediated homotypic cell-cell adhesion and contributes to the regulation of downstream signaling pathways. Promotes cell migration. Contributes to the regulation of the inflammatory response. MGAT5-dependent TCR N-glycosylation enhances the interaction between TCR and LGALS3, limits agonist-induced TCR clustering, and thereby dampens TCR-mediated responses to antigens. Required for normal leukocyte evasation and accumulation at sites of inflammation (By similarity). Inhibits attachment of monocytes to the vascular endothelium and subsequent monocyte diapedesis . .; FUNCTION: [Secreted alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A]: Promotes proliferation of umbilical vein endothelial cells and angiogenesis, at least in part by promoting the release of the growth factor FGF2 from the extracellular matrix. . |
Accessions | Q53SZ9 Q09328 Q53SM9 ENST00000281923.4 Q53SV8 ENST00000409645.5 |